| Literature DB >> 16902292 |
M Iijima1, H Uhara, Y Ide, S Sakai, H Onuma, M Muto, K Hayashi, F Mitsura, S Kobayashi, A Yoshizawa, T Saida.
Abstract
The patient was an 80-year-old man with scrotal and penile extramammary Paget's disease and prostate cancer. Both diseases were in advanced stages. Tumor cells of extramammary Paget's disease strongly expressed estrogen receptor alpha. The patient was concurrently treated with two kinds of hormonal therapy: the anti-estrogen tamoxifen (20 mg/day orally) for extramammary Paget's disease and the anti-androgen bicalutamide (80 mg/day orally) for prostate cancer. The toxicity of the therapy was mild. All of the metastatic lesions remained stable for 2 months after initiation of dual hormonal therapy. During a follow-up period of 22 months, performance status was well maintained for 17 months. Hormonal therapy may be an alternative for selected cases of advanced extramammary Paget's disease. Copyright 2006 S. Karger AG, Basel.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16902292 DOI: 10.1159/000093854
Source DB: PubMed Journal: Dermatology ISSN: 1018-8665 Impact factor: 5.366